FDA, Reagan-Udall Foundation for the FDA to Hold Important Public Workshop to Discuss Naloxone Access
FDA Has Taken Several Steps in Recent Years to Support Increased Availability of Opioid Overdose Reversal Drug
The U.S. Food and Drug Administration will host a virtual public workshop on Mar. 29, to discuss critical questions around access to naloxone, a drug used to reverse opioid overdoses. The workshop is a collaboration with the Reagan-Udall Foundation for the FDA.
“An integral part of our efforts to combat opioid-related drug overdose is making naloxone more readily available and accessible,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research.
Read the full announcement here.
Learn more about the March 29th event here.